Health Care • Medical Specialities
$178.80 ▼ -6.51
(-3.51%)
MKT CAP: $23.99B • VOL: 1.50M
52W L $75 52W H $191
GH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $982.0M | $739.0M | $563.9M |
| YoY Revenue Growth % | +32.9% | +31.0% | — |
| Gross Profit | $633.0M | $449.2M | — |
| Gross Margin % | 64.5% | 60.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$437.2M | -$443.6M | -$564.7M |
| Operating Margin % | -44.5% | -60.0% | -100.1% |
| Net Income (GAAP) | -$416.3M | -$436.4M | -$479.4M |
| EBITDA (Normalized) | -$398.6M | -$415.5M | -$544.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$184.8M | -$239.9M | -$325.0M |
| Capital Expenditures (CapEx) | $48.3M | $35.1M | $25.4M |
| Free Cash Flow (FCF) | -$233.1M | -$274.9M | -$350.4M |
| FCF Margin % | -23.7% | -37.2% | -62.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -5.4% |
| Cash & Short-Term Equivalents | $378.2M | $525.5M | — |
| Total Debt (Short + Long Term) | $950.8M | $731.4M | $3.20B |
| Total Stockholders' Equity | -$99.3M | -$139.6M | $6.57B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GH.